{"id":742309,"date":"2013-10-01T09:00:00","date_gmt":"2013-10-01T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/"},"modified":"2023-03-22T00:04:34","modified_gmt":"2023-03-22T04:04:34","slug":"data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/","title":{"rendered":"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of data from studies evaluating the<br \/>\n      company\u2019s investigational oral chronic hepatitis C virus (HCV)<br \/>\n      treatments MK-5172 and MK-8742 at the 64<sup>th<\/sup> American<br \/>\n      Association for the Study of Liver Diseases Annual Meeting (AASLD). The<br \/>\n      meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013.\n    <\/p>\n<p>\n      \u201cMerck is committed to developing HCV therapies that have the potential<br \/>\n      to offer new options for a broad range of patient types,\u201d said Dr. Eliav<br \/>\n      Barr, vice president, Infectious Diseases, Merck Research Laboratories.<br \/>\n      \u201cWe continue to build upon our strong legacy in HCV and look forward to<br \/>\n      sharing the latest clinical data for our investigational HCV therapies,<br \/>\n      MK-5172 and MK-8742.\u201d\n    <\/p>\n<p>\n      MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease<br \/>\n      inhibitor currently in Phase IIB development. MK-8742 is an<br \/>\n      investigational, once-daily, oral HCV NS5A replication complex inhibitor<br \/>\n      currently in Phase IIB development. Both candidates are being evaluated<br \/>\n      in broad clinical programs that include investigations in various HCV<br \/>\n      segments, multiple HCV genotypes and patients who have previously failed<br \/>\n      prior therapy.\n    <\/p>\n<p>\n      <b>Selected presentations of clinical data for MK-5172 and MK-8742<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        High Efficacy and Safety of the All-Oral Combination Regimen,<br \/>\n        MK-5172\/MK-8742 +\/- RBV for 12 Weeks in HCV Genotype 1 Infected<br \/>\n        Patients: The C-WORTHY Study. Lawitz, E., et al. Oral Presentation<br \/>\n        #76: Sunday, Nov. 3, 2013, 5:30-5:45 p.m.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal<br \/>\n        Early and Potent Inhibition of Viral Assembly and Release. McGivern,<br \/>\n        D.R., et al. Oral Presentation #78: Sunday, Nov. 3, 2013, 6:00-6:15<br \/>\n        p.m.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        High Efficacy at Lower Doses of MK-5172 25mg and 50mg Daily for 12<br \/>\n        weeks in HCV Genotype (G) 1 Treatment-Na\u00efve Non-Cirrhotic Patients.<br \/>\n        Vierling, J., N et al. Poster #1123. Sunday, Nov. 3, 2013, 8:00 a.m.<br \/>\n        to 5:30 p.m.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Efficacy and Safety of an Interferon-Free Regimen of MK-5172 +<br \/>\n        Ribavirin for 12 Weeks or 24 Weeks in Treatment-Na\u00efve, Non-Cirrhotic<br \/>\n        Subjects with HCV GT1 Infection: The C-SPIRIT Study. Gane, E.J., et<br \/>\n        al., Poster #1110. Sunday, Nov. 3, 2013, 8:00 a.m. to 5:30 p.m.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-8742, a HCV NS5A Inhibitor with a Broad Spectrum of HCV Genotypic<br \/>\n        Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3<br \/>\n        HCV-Infected Patients. Yeh, W. W., et al. Poster #479. Saturday, Nov.<br \/>\n        2, 2013, 2:00-7:30 p.m.\n      <\/li>\n<\/ul>\n<p>\n      The abstracts were published today and can be accessed on the AASLD<br \/>\n      website. For program information, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.aasld.org%2Flivermeeting%2Fprogram%2FPages%2Fdefault.aspx&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.aasld.org%2Flivermeeting%2Fprogram%2FPages%2Fdefault.aspx&#038;index=1&#038;md5=d1f8e79cf3069a056f203f3be93a5f07\" rel=\"nofollow\">http:\/\/www.aasld.org\/livermeeting\/program\/Pages\/default.aspx<\/a>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=b9b6f9fbd627c2b5a30842ed1229b8d1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=637b4f936760249247794a50e2a85d99\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=886e2725b3ef28f4e67793ba9206c58d\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=fd819480e91712deaa3fa1a2cb0541a0\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov%2F&#038;esheet=50720032&#038;newsitemid=20131001006261&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=623d98d51b82ae105d3633a23362636b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Revatio<\/b><sup><b>\u00ae<\/b><\/sup><b> and Adcirca<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      are trademarks of their respective owners and are not trademarks of<br \/>\n      Merck &#038; Co., Inc., Whitehouse Station, N.J., USA.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131001006261r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Sarra Herzog, 908-423-6154<br \/>or<br \/>Investor:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company\u2019s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64 th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. \u201cMerck is committed to developing HCV therapies that have the potential to offer new options for a broad range of patient types,\u201d said Dr. Eliav Barr, vice president, Infectious Diseases, Merck Research Laboratories. \u201cWe continue to build upon our strong legacy in HCV and look forward to sharing the latest clinical data for our investigational HCV therapies, MK-5172 and MK-8742.\u201d MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease inhibitor currently in Phase IIB development. MK-8742 is an investigational, once-daily, oral HCV NS5A replication complex inhibitor currently in<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742309","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company\u2019s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64 th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. \u201cMerck is committed to developing HCV therapies that have the potential to offer new options for a broad range of patient types,\u201d said Dr. Eliav Barr, vice president, Infectious Diseases, Merck Research Laboratories. \u201cWe continue to build upon our strong legacy in HCV and look forward to sharing the latest clinical data for our investigational HCV therapies, MK-5172 and MK-8742.\u201d MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease inhibitor currently in Phase IIB development. MK-8742 is an investigational, once-daily, oral HCV NS5A replication complex inhibitor currently in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/\",\"name\":\"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-10-01T09:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company\u2019s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64 th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. \u201cMerck is committed to developing HCV therapies that have the potential to offer new options for a broad range of patient types,\u201d said Dr. Eliav Barr, vice president, Infectious Diseases, Merck Research Laboratories. \u201cWe continue to build upon our strong legacy in HCV and look forward to sharing the latest clinical data for our investigational HCV therapies, MK-5172 and MK-8742.\u201d MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease inhibitor currently in Phase IIB development. MK-8742 is an investigational, once-daily, oral HCV NS5A replication complex inhibitor currently in","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:34+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/","name":"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx","datePublished":"2013-10-01T09:00:00+00:00","dateModified":"2023-03-22T04:04:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131001006261r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-from-mercks-investigational-hepatitis-c-treatment-portfolio-to-be-presented-at-the-64th-american-association-for-the-study-of-liver-diseases-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Data from Merck\u2019s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e723d65b-0bc0-48c7-a25f-a4d9b195810f","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742309\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742309"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}